Neon Therapeutics (NASDAQ:NTGN) Price Target Raised to $12.00 at HC Wainwright

Neon Therapeutics (NASDAQ:NTGN) had its price target lifted by HC Wainwright from $10.00 to $12.00 in a research report sent to investors on Tuesday, The Fly reports. HC Wainwright currently has a buy rating on the stock.

A number of other equities analysts have also recently commented on the stock. Zacks Investment Research upgraded shares of Golub Capital BDC from a hold rating to a buy rating and set a $20.00 target price on the stock in a research report on Tuesday. Mizuho set a $21.00 target price on shares of Neon Therapeutics and gave the stock a buy rating in a research report on Monday, July 1st. Finally, Berenberg Bank decreased their target price on shares of Lucara Diamond from C$1.60 to C$1.50 in a research report on Wednesday, March 27th. Two investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The stock presently has an average rating of Buy and an average target price of $16.00.

NASDAQ:NTGN traded down $0.40 during trading hours on Tuesday, reaching $3.73. The company’s stock had a trading volume of 6,821 shares, compared to its average volume of 193,300. The company has a market capitalization of $122.39 million and a price-to-earnings ratio of -0.66. The firm’s 50-day moving average price is $4.70. Neon Therapeutics has a 1 year low of $4.08 and a 1 year high of $13.00. The company has a debt-to-equity ratio of 0.09, a current ratio of 7.30 and a quick ratio of 7.30.



Neon Therapeutics (NASDAQ:NTGN) last issued its earnings results on Monday, May 13th. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.03). Research analysts expect that Neon Therapeutics will post -2.69 EPS for the current year.

Several hedge funds have recently added to or reduced their stakes in the business. FMR LLC increased its position in shares of Neon Therapeutics by 1.1% in the fourth quarter. FMR LLC now owns 2,079,669 shares of the company’s stock valued at $10,461,000 after acquiring an additional 23,075 shares during the period. BlackRock Inc. increased its position in shares of Neon Therapeutics by 12.0% in the fourth quarter. BlackRock Inc. now owns 307,782 shares of the company’s stock valued at $1,548,000 after acquiring an additional 32,943 shares during the period. Northern Trust Corp increased its position in shares of Neon Therapeutics by 68.9% in the fourth quarter. Northern Trust Corp now owns 88,678 shares of the company’s stock valued at $446,000 after acquiring an additional 36,170 shares during the period. Geode Capital Management LLC increased its position in shares of Neon Therapeutics by 127.0% in the fourth quarter. Geode Capital Management LLC now owns 60,309 shares of the company’s stock valued at $303,000 after acquiring an additional 33,741 shares during the period. Finally, Acadian Asset Management LLC purchased a new position in shares of Neon Therapeutics in the first quarter valued at about $268,000. Hedge funds and other institutional investors own 69.57% of the company’s stock.

Neon Therapeutics Company Profile

Neon Therapeutics, Inc, a clinical-stage immuno-oncology company, engages in developing neoantigen-targeted therapies for cancers in the United States. It is developing NEO-PV-01, a neoantigen vaccine that is in Phase Ib clinical trial in combination with nivolumab for the treatment of metastatic melanoma, non-small cell lung cancer, and bladder cancer; NEO-PTC-01, a neoantigen T cell therapy for the treatment of solid tumors; and NEO-SV-01, a neoantigen vaccine for the treatment of estrogen-receptor-positive breast cancer.

Further Reading: Dividend Aristocrat Index

The Fly

Analyst Recommendations for Neon Therapeutics (NASDAQ:NTGN)

Receive News & Ratings for Neon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.